Indaptus Therapeutics, Inc. — FY2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023; comparisons are with FY2022. The company is a clinical-stage biotechnology business developing immunotherapies and has no approved products or product-sales revenue.
Business context and development
Lead candidate Decoy20 is an investigational, intravenously administered therapy made from attenuated, killed, non-pathogenic Gram-negative bacteria, intended to activate innate and adaptive immune responses. Its Phase 1 trial in patients with advanced solid tumors began in December 2022. In 2023, four patients completed the first single-dose cohort; reported symptoms or adverse events were short-lived and consistent with the proposed mechanism. The second cohort was completed in early March 2024, after which the company advanced to a multi-dosing cohort following Safety Review Committee authorization. The filing reports no efficacy conclusion from these early cohorts.
Financial results and liquidity
| Metric | FY2023 / Dec. 31, 2023 | FY2022 / Dec. 31, 2022 |
|---|---|---|
| Revenue from product sales | None | None |
| Research and development expense | $7.62 million | $6.32 million |
| General and administrative expense | $8.76 million | $8.59 million |
| Total operating expenses / operating loss | $16.38 million | $14.91 million |
| Other income, net | $0.96 million | $0.59 million |
| Net loss | $15.42 million; $1.83 per share | $14.32 million; $1.73 per share |
| Cash and cash equivalents | $13.36 million | $9.63 million |
| Marketable securities | None | $16.81 million |
| Total assets | $14.92 million | $28.06 million |
| Total liabilities | $2.85 million | $3.43 million |
Operating cash use was $13.41 million in 2023, versus $13.08 million in 2022. Investing activities provided $17.14 million, principally reflecting $24.0 million in maturities of marketable securities and $6.86 million in purchases. There was no net cash from financing activities in either year. The filing reports no revenue-based margins; profitability and operating margins are not meaningful for this pre-revenue company.
No funded debt is identified in the supplied financial statements. Lease liabilities totaled approximately $175,000 at year-end; future minimum lease payments were approximately $189,000. The company reported a $45.42 million accumulated deficit and $12.08 million in stockholders’ equity.
Changes versus FY2022
- Net loss increased $1.10 million, or 8%; total operating expenses increased 10%.
- R&D expense rose 21%, mainly from Phase 1 trial and pipeline costs and increased payroll; G&A rose 2%.
- Other income increased to $0.96 million, primarily due to higher interest income, partly offset by a lower contribution from a contractual-dispute settlement. The settlement timing and income recognition are described inconsistently in the MD&A and notes; verify against the financial statements and notes.
- Cash and cash equivalents increased from $9.63 million, but the company had no marketable securities at year-end, compared with $16.81 million in 2022. Total assets and equity declined materially, principally amid operating losses and the use of securities to fund operations.
Outlook, risks and unusual items
- Management estimates year-end cash and cash equivalents will fund operating expenses and capital needs through the third quarter of 2024. It expects R&D and G&A expenses to increase as clinical development and staffing expand; no earnings or revenue guidance is provided.
- Management and the auditor identify substantial doubt about the company’s ability to continue as a going concern. The company expects to seek collaborations, licensing arrangements, and/or debt or equity financing, but availability and terms are uncertain. Failure to secure funding could force delays, reductions or termination of development programs, or cessation of operations.
- Financing capacity includes an ATM facility of up to $3.7 million and a Lincoln Park purchase agreement for up to $20 million, subject to conditions and limitations. The filing reports no shares sold under Lincoln Park. In March 2024, the company sold 137,836 shares under the ATM for gross proceeds of approximately $0.3 million.
- Key risks include clinical and regulatory uncertainty, potential immune-related adverse effects, reliance on CROs and third-party manufacturers, limited cash runway, potential shareholder dilution, competition, and intellectual-property and reimbursement risks.
- The audited financial statements received an unqualified opinion, with a going-concern paragraph; the auditor reported no critical audit matters. Management stated that disclosure controls and internal control over financial reporting were effective as of December 31, 2023. No auditor attestation on internal controls was included under the company’s applicable exemption.
Important facts for investors to verify
- Current cash runway, spending pace, and whether financing or collaboration proceeds have extended the stated runway beyond Q3 2024.
- Decoy20 trial enrollment, dose levels, safety findings, and the timing and completeness of multi-dose and subsequent clinical data.
- Terms, remaining capacity, share issuance and potential dilution from the ATM and Lincoln Park arrangements; reconcile the March 2024 ATM sale with the reported share count of 8,538,883 as of March 12, 2024.
- The settlement’s timing and accounting treatment, given the difference between the MD&A description and the note disclosure.
- Clinical manufacturing and trial costs, and whether the company can fund planned development without materially reducing or delaying programs.